148 related articles for article (PubMed ID: 29187435)
1. Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells.
Mayer MJ; Klotz LH; Venkateswaran V
Anticancer Res; 2017 Dec; 37(12):6601-6607. PubMed ID: 29187435
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
Mayer MJ; Klotz LH; Venkateswaran V
J Urol; 2017 Apr; 197(4):1068-1075. PubMed ID: 27984108
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
4. Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.
Babcook MA; Shukla S; Fu P; Vazquez EJ; Puchowicz MA; Molter JP; Oak CZ; MacLennan GT; Flask CA; Lindner DJ; Parker Y; Daneshgari F; Gupta S
Mol Cancer Ther; 2014 Oct; 13(10):2288-302. PubMed ID: 25122066
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer.
Zhu S; Oremo JA; Li S; Zhen M; Tang Y; Du Y
PLoS One; 2014; 9(3):e91817. PubMed ID: 24632829
[TBL] [Abstract][Full Text] [Related]
6. Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Biernacka KM; Persad RA; Bahl A; Gillatt D; Holly JM; Perks CM
Endocr Relat Cancer; 2017 Jan; 24(1):17-30. PubMed ID: 27754854
[TBL] [Abstract][Full Text] [Related]
7. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
8. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
9. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
[No Abstract] [Full Text] [Related]
10. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
[TBL] [Abstract][Full Text] [Related]
11. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.
Babcook MA; Sramkoski RM; Fujioka H; Daneshgari F; Almasan A; Shukla S; Nanavaty RR; Gupta S
Cell Death Dis; 2014 Nov; 5(11):e1536. PubMed ID: 25412314
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells.
Wang Q; He WY; Zeng YZ; Hossain A; Gou X
Int Urol Nephrol; 2018 Apr; 50(4):675-686. PubMed ID: 29460131
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitizing Effect and Efficacy of Wilforlide A in Combination With Docetaxel in Drug-resistant Prostate Cancer.
Wang Z; Yeung S; Yang S; Huang Y; Sum Chow MS
In Vivo; 2022; 36(5):2020-2031. PubMed ID: 36099129
[TBL] [Abstract][Full Text] [Related]
14. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
15. Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves.
Marano F; Rinella L; Argenziano M; Cavalli R; Sassi F; D'Amelio P; Battaglia A; Gontero P; Bosco O; Peluso R; Fortunati N; Frairia R; Catalano MG
PLoS One; 2016; 11(12):e0168553. PubMed ID: 28002459
[TBL] [Abstract][Full Text] [Related]
16. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
Cardillo I; Spugnini EP; Galluzzo P; Contestabile M; Dell'Anna ML; Picardo M; Crispi S; Calogero RA; Piccolo MT; Arigoni M; Cantarella D; Boccellino M; Quagliuolo L; Ferretti G; Carlini P; Felici A; Boccardo F; Cognetti F; Baldi A
Future Oncol; 2013 Sep; 9(9):1375-88. PubMed ID: 23980684
[TBL] [Abstract][Full Text] [Related]
17. Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel.
Li K; Mao Y; Lu L; Hu C; Wang D; Si-Tu J; Lu M; Peng S; Qiu J; Gao X
Int J Oncol; 2016 Oct; 49(4):1679-85. PubMed ID: 27633058
[TBL] [Abstract][Full Text] [Related]
18. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
19. The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
Jeong CW; Yoon CY; Jeong SJ; Hong SK; Byun SS; Kwak C; Lee SE
Urol Oncol; 2013 Nov; 31(8):1448-56. PubMed ID: 22537539
[TBL] [Abstract][Full Text] [Related]
20. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
